Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point of care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

For more information, click below.


Subscribers log in here


Clinical manifestations and diagnosis of analgesic nephropathy

INTRODUCTION

Analgesic nephropathy is a renal disease characterized by papillary necrosis and chronic interstitial nephritis, and caused by the long-term consumption of analgesic agents [1]. According to one definition, analgesic nephropathy results from the use of combination agents that contain two or more analgesics agents, and usually codeine or caffeine [2]. However, many believe that analgesic nephropathy may result from ingestion of any single analgesic agent that is taken long term [2]. The use of phenacetin, which is no longer available, was particularly associated with analgesic nephropathy [3].

The manifestations, diagnosis, differential diagnosis, and prognosis of analgesic nephropathy are reviewed here. The epidemiology, risk factors, and the associations with urinary tract malignancy and atherosclerotic cardiovascular disease are discussed separately. (See "Risk factors for and pathogenesis of analgesic nephropathy", section on 'Importance of phenacetin' and "Urinary tract malignancy and atherosclerotic disease in patients with chronic analgesic abuse".)

EPIDEMIOLOGY

Analgesic nephropathy used to be one of the more common causes of chronic kidney disease, particularly in Australia and parts of Europe and the United States, but there was a marked decline in prevalence in the 1990s [4]. The decrease in prevalence was likely due to the withdrawal of phenacetin from the market and to legislation that made combined analgesics available only by prescription [5-7]. As an illustrative example, a Swiss autopsy study performed between 2000 and 2002, revealed medullary findings characteristic of analgesic nephropathy in only 0.2 percent of autopsies [5], compared with a prevalence of 3 percent cited by the same group in a study performed in 1983 [8]. It is not clear whether the marked decline in prevalence was due to the withdrawal of phenacetin in 1983, or to subsequent legislation that mandated the requirement for a prescription for combination agents [9].

CLINICAL FEATURES

Clinical manifestations — Most patients who present with analgesic nephropathy are older than 45 years of age [10]. Usually patients have no symptoms and the disease is incidentally detected by laboratory studies that are performed for an unrelated problem and show an elevated creatinine or abnormal urinalysis.

Patients often have a history of chronic headaches or low back pain that leads to the analgesic use. Other common problems include somatic complaints such as malaise and weakness, and a history of peptic ulcer disease that may be related, in part, to aspirin and/or nonsteroidal antiinflammatory drug ingestion [1]. The frequency of reported history varies between studies [1]. In a review of studies from Europe and the United States, headache was present in 35 to 100 percent and gastrointestinal symptoms were reported in 40 to 60 percent of patients [1,11-15].

      

Subscribers log in here

To continue reading this article you must have access through your hospital or your group practice, log in to your personal subscription, or purchase a personal subscription. For more information, click below.
Literature review current through: Apr 2013. | This topic last updated: Dec 10, 2012.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2013 UpToDate, Inc.
References
Top
  1. Murray TG, Goldberg M. Analgesic-associated nephropathy in the U.S.A.: epidemiologic, clinical and pathogenetic features. Kidney Int 1978; 13:64.
  2. Henrich WL, Agodoa LE, Barrett B, et al. Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis 1996; 27:162.
  3. GLOOR F. [Phenacetin abuse and kidney damage]. Schweiz Med Wochenschr 1962; 92:61.
  4. De Broe ME, Elseviers MM. Analgesic nephropathy. N Engl J Med 1998; 338:446.
  5. Mihatsch MJ, Khanlari B, Brunner FP. Obituary to analgesic nephropathy--an autopsy study. Nephrol Dial Transplant 2006; 21:3139.
  6. Noels LM, Elseviers MM, de Broe ME. Impact of legislative measures on the sales of analgesics and the subsequent prevalence of analgesic nephropathy: a comparative study in France, Sweden and Belgium. Nephrol Dial Transplant 1995; 10:167.
  7. Brunner FP, Selwood NH. End-stage renal failure due to analgesic nephropathy, its changing pattern and cardiovascular mortality. EDTA-ERA Registry Committee. Nephrol Dial Transplant 1994; 9:1371.
  8. Mihatsch MJ, Hofer HO, Korteweg E, Zollinger HU. [Phenacetin abuse V: number of phenacetin abusers in Basel autopsy material 1978-1980. Results of a prospective study]. Schweiz Med Wochenschr 1982; 112:1245.
  9. De Broe ME, Elseviers MM. Over-the-counter analgesic use. J Am Soc Nephrol 2009; 20:2098.
  10. Vadivel N, Trikudanathan S, Singh AK. Analgesic nephropathy. Kidney Int 2007; 72:517.
  11. Fellner SK, Tuttle EP. The clinical syndrome of analgesic abuse. Arch Intern Med 1969; 124:379.
  12. Murray T, Goldberg M. Chronic interstitial nephritis: etiologic factors. Ann Intern Med 1975; 82:453.
  13. Gault MH, Blennerhassett J, Muehrcke RC. Analgesic nephropathy. A clinicopathologic study using electron microscopy. Am J Med 1971; 51:740.
  14. Olafsson O, Gudmundsson KR, Brekkan A. Migraine, gastritis and renal papillary necrosis. A syndrome in chronic nonobstructive pyelonephritis. Acta Med Scand 1966; 179:121.
  15. Prescott LF. Analgesic abuse and renal disease in North-East Scotland. Lancet 1966; 2:1143.
  16. Nanra RS, Stuart-Taylor J, de Leon AH, White KH. Analgesic nephropathy: etiology, clinical syndrome, and clinicopathologic correlations in Australia. Kidney Int 1978; 13:79.
  17. Elseviers MM, De Schepper A, Corthouts R, et al. High diagnostic performance of CT scan for analgesic nephropathy in patients with incipient to severe renal failure. Kidney Int 1995; 48:1316.
  18. Elseviers MM, Bosteels V, Cambier P, et al. Diagnostic criteria of analgesic nephropathy in patients with end-stage renal failure: results of the Belgian study. Nephrol Dial Transplant 1992; 7:479.
  19. Sugiura T, Nakamori A, Wada A, Fukuhara Y. Evaluation of tubulointerstitial injury by Doppler ultrasonography in glomerular diseases. Clin Nephrol 2004; 61:119.
  20. Elseviers MM, Waller I, Nenoy D, et al. Evaluation of diagnostic criteria for analgesic nephropathy in patients with end-stage renal failure: results of the ANNE study. Analgesic Nephropathy Network of Europe. Nephrol Dial Transplant 1995; 10:808.
  21. Pintér I, Mátyus J, Czégány Z, et al. Analgesic nephropathy in Hungary: the HANS study. Nephrol Dial Transplant 2004; 19:840.
  22. Henrich WL, Clark RL, Kelly JP, et al. Non-contrast-enhanced computerized tomography and analgesic-related kidney disease: report of the national analgesic nephropathy study. J Am Soc Nephrol 2006; 17:1472.
  23. Mackinnon B, Boulton-Jones M, McLaughlin K. Analgesic-associated nephropathy in the West of Scotland: a 12-year observational study. Nephrol Dial Transplant 2003; 18:1800.
  24. Matousovic K, Elseviers MM, Devecka D, et al. Incidence of analgesic nephropathy among patients undergoing renal replacement therapy in Czech Republic and Slovak Republic. The Group of Czech and Slovak Nephrologists. Nephrol Dial Transplant 1996; 11:1048.
  25. Mátyus J, Ujhelyi L, Kárpáti I, et al. Increase in the incidence of analgesic nephropathy in Hungary. Nephrol Dial Transplant 1997; 12:1774.
  26. Franek E, Kokot F, Grzeszczak W, Gajos L. Is analgesic nephropathy a problem in the south-west region of Poland? Nephron 1996; 72:353.
  27. Buckalew VM Jr, Schey HM. Renal disease from habitual antipyretic analgesic consumption: an assessment of the epidemiologic evidence. Medicine (Baltimore) 1986; 65:291.
  28. Gault MH, Wilson DR. Analgesic nephropathy in Canada: clinical syndrome, management, and outcome. Kidney Int 1978; 13:58.
  29. Sandler DP, Smith JC, Weinberg CR, et al. Analgesic use and chronic renal disease. N Engl J Med 1989; 320:1238.
  30. Garber SL, Mirochnik Y, Arruda JA, Dunea G. Evolution of experimentally induced papillary necrosis to focal segmental glomerulosclerosis and nephrotic proteinuria. Am J Kidney Dis 1999; 33:1033.